Poseida Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Poseida Therapeutics generated cash of -$92,167,000, which is less than the previous year. Cash used in financing activities reached the amount of $16,126,999 last year. Net change in cash is therefore -$36,906,000.
Cash Flow
| 2017 | -22.69M | -201K | 20.63M |
|---|---|---|---|
| 2018 | -38.01M | -1.28M | 54.06M |
| 2019 | -64.39M | -42.59M | 164.37M |
| 2020 | -113.32M | -204.43M | 313.94M |
| 2021 | -102.54M | 222.38M | 2.51M |
| 2022 | -26.77M | -203.33M | 105.15M |
| 2023 | -92.16M | 39.13M | 16.12M |
PSTX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 81.37M | 206.32M | 83.96M | 87.78M | 30.39M | 15.62M | 17.89M |
Operating activities | |||||||
Net income | -123.43M | -64.00M | -124.97M | -129.77M | -86.52M | -44.40M | -19.66M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 5.61M | 5.17M | 4.55M | 2.58M | 1.19M | 689K | 676K |
Stock-based compensation expense | 23.13M | 18.92M | 16.70M | 7.22M | 3.05M | 975K | 400K |
| Deferred income tax benefit | 23.13M | 18.92M | 16.70M | 7.22M | 3.05M | 975K | 400K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 77K | -9.08M | 0 | 0 | 0 | 0 | 865K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | -124K |
Accounts payable | 1.03M | -6.74M | 7.84M | -4.17M | 1.53M | 1.00M | -41K |
Cash generated by operating activities | -92.16M | -26.77M | -102.54M | -113.32M | -64.39M | -38.01M | -22.69M |
Investing activities | |||||||
Purchases Of Investments | -237.8M | -294.42M | -18K | -295.02M | -71.43M | 0 | 0 |
Investments In Property Plant And Equipment | -3.06M | -3.92M | -2.63M | -16.90M | -5.15M | -1.28M | -201K |
Acquisitions Net | 0 | 12K | 18K | 187.52M | 37.30M | 0 | 0 |
Cash generated by investing activities | 39.13M | -203.33M | 222.38M | -204.43M | -42.59M | -1.28M | -201K |
Financing activities | |||||||
Common Stock Issued | 15.34M | 75.29M | 2.51M | 205.74M | 149.78M | 0 | 11.44M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 30M | 0 | 0 | 10M | 0 | 10M |
Cash used in financing activities | 16.12M | 105.15M | 2.51M | 313.94M | 164.37M | 54.06M | 20.63M |
Net Change In Cash | -36.90M | -124.94M | 122.35M | -3.81M | 57.38M | 14.77M | -2.26M |
Cash at end of period | 44.47M | 81.37M | 206.32M | 83.96M | 87.78M | 30.39M | 15.62M |
| Data source | Data source | Data source | Data source |